L
Lineage Cell Therapeutics Inc
XBER:BT3
Lineage Cell Therapeutics Inc
XBER:BT3
Price:
1.35
EUR
Market Closed
Market Cap:
€395.1m
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
L
|
Lineage Cell Therapeutics Inc
XBER:BT3
|
US |
|
Caixabank SA
MAD:CABK
|
ES |
|
Oryzon Genomics SA
MAD:ORY
|
ES |
|
Thomson Reuters Corp
F:TOC
|
CA |
|
Toyota Motor Corp
F:TOM
|
JP |
|
Avolta AG
SIX:AVOL
|
CH |
|
Toyo Tanso Co Ltd
OTC:TYOTF
|
JP |
|
UPL Ltd
LSE:UPLL
|
IN |
|
Taiwan Semiconductor Manufacturing Co Ltd
TWSE:2330
|
TW |
|
N
|
Novo Nordisk A/S
SWB:NOVA
|
DK |
|
Reckitt Benckiser Group PLC
F:3RB
|
UK |
|
U
|
United Therapeutics Corp
F:UTH
|
US |
|
F
|
Fortescue Ltd
XMUN:FVJ
|
AU |
|
R
|
Regis Corp
XBER:RGI
|
US |
|
H
|
Harmony Gold Mining Company Ltd
XBER:HAM1
|
ZA |
|
B
|
Baker Hughes Co
SIX:BHI
|
US |
|
B
|
B2holding ASA
OSE:B2H
|
NO |
Wall St Price Targets
BT3 Price Targets Summary
Lineage Cell Therapeutics Inc
Lineage Cell Therapeutics Inc
Wall Street analysts forecast BT3 stock price to rise over the next 12 months.
According to Wall Street analysts, the average 1-year price target for BT3 is 6.01 EUR with a low forecast of 3.25 EUR and a high forecast of 10.12 EUR.
Lowest Forecast
Price Target
3.25
EUR
140% Upside
Average Forecast
Price Target
6.01
EUR
345% Upside
Highest Forecast
Price Target
10.12
EUR
650% Upside
Why do you have more estimates than other sites?
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is BT3's stock price target?
Price Target
6.01
EUR
6.01
EUR
According to Wall Street analysts, the average 1-year price target for BT3 is 6.01 EUR with a low forecast of 3.25 EUR and a high forecast of 10.12 EUR.
What is the Revenue forecast for Lineage Cell Therapeutics Inc?
Projected CAGR
58%
58%
Over the last 14 years, the compound annual growth rate for Revenue has been 9%. The projected CAGR for the next 8 years is 58%.
